Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 50228-139

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 50228-139). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig.1 (Donepezil Figure 01)

Chemical structure of Donepezil Hydrochloride, showing the molecular arrangement including methoxy groups, a piperidine ring, a benzyl group, and the hydrochloride component.*

FDA Label Image

3 (Donepezil Figure 02)

A line graph showing ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) change from baseline over 18 weeks of drug treatment with Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The vertical axis represents mean change from baseline, with clinical improvement indicated upwards and clinical decline downwards. The horizontal axis shows treatment duration in weeks. Data points include error bars.*

FDA Label Image

4 (Donepezil Figure 03)

A cumulative percentage plot showing patient responses to Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo. The x-axis represents change from baseline in ADAS-cog scores, while the y-axis shows the cumulative percentage of patients. The chart includes markers for 7 points, 4 points, and no change, with treatment group response percentages indicated in an inset table.*

FDA Label Image

5 (Donepezil Figure 04)

Bar graph depicting CIBIC-plus rating distribution by percentage of patients for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and Placebo groups. Ratings range from Markedly Improved to Markedly Worse, showing patient outcomes across these treatment arms.*

FDA Label Image

6 (Donepezil Figure 05)

Line graph showing ADAS-cog change from baseline over 12 weeks of treatment with Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo in a clinical trial. Y-axis represents cognitive change, with clinical improvement and decline labeled. The graph shows mean ± SE values at weeks 0, 3, 6, 9, and 12, with Donepezil groups improving relative to placebo.*

FDA Label Image

7 (Donepezil Figure 06)

A cumulative percentage of patients chart comparing the effects of Donepezil Hydrochloride 5 mg/day and 10 mg/day to placebo on change from baseline in ADAS-cog scores. The graph plots cumulative percentage of patients against change from baseline and includes thresholds for 7 points, 4 points improvement, and no change, alongside a table showing percentages of patients at these change levels by treatment group.*

FDA Label Image

8 (Donepezil Figure 07)

A bar chart showing the percentage of patients by clinical outcome categories on the CIBIC-plus Rating scale for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. Categories range from Markedly Improved to Markedly Worse, with the highest percentages in No Change and Minimal Improvement categories.*

FDA Label Image

9 (Donepezil Figure 08)

A line graph depicting SIB change from baseline over 6 months of drug treatment. It compares Donepezil Hydrochloride 10 mg/day with placebo, showing mean change ±SE. The graph indicates clinical improvement and decline relative to baseline, with Donepezil showing improvement and placebo showing decline.*

FDA Label Image

10 (Donepezil Figure 09)

A cumulative percentage of patients graph comparing Donepezil Hydrochloride 10 mg/day and placebo. The x-axis shows SIB (Severe Impairment Battery) change from baseline, while the y-axis shows the cumulative percentage of patients. Donepezil Hydrochloride data points are marked with filled circles, and placebo with open squares. The graph illustrates treatment response distribution in patients.*

FDA Label Image

11 (Donepezil Figure 10)

A line graph showing the effect of Donepezil Hydrochloride Tablets 10 mg/day versus placebo on ADCS-ADL scores over 6 months of drug treatment. The vertical axis represents mean change from baseline, ranging from clinical improvement to clinical decline, while the horizontal axis shows months of treatment. The graph shows less clinical decline for the Donepezil group compared to placebo over time.*

FDA Label Image

18 (Donepezil Figure 11)

A cumulative percentage graph showing ADCS-ADL change from baseline on the horizontal axis versus cumulative percentage of patients on the vertical axis. The graph compares Donepezil Hydrochloride 10 mg/day treatment (solid circles) with placebo (open squares), illustrating higher cumulative patient response rates for Donepezil Hydrochloride compared to placebo.*

FDA Label Image

19 (Donepezil Figure 12)

A line graph comparing SIB change from baseline (LS mean ± SE) over 24 weeks of drug treatment for Donepezil Hydrochloride 23 mg/day and 10 mg/day. The graph shows clinical improvement at positive values and clinical decline at negative values, with data points at 0, 6, 12, 18, and 24 weeks.*

FDA Label Image

20 (Donepezil Figure 13)

A cumulative percentage of patients chart showing SIB (Severe Impairment Battery) change from baseline on the horizontal axis and cumulative percentage on the vertical axis. Two curves compare Donepezil Hydrochloride dosages of 10 mg/day and 23 mg/day, indicating patient response distributions across these doses.*

FDA Label Image

5 mg (Donepezil Figure 14)

A bar chart comparing the percentage of patients at various CIBIC-plus rating levels between Donepezil Hydrochloride Tablets 23 mg/day and 10 mg/day. The chart shows patient outcome categories ranging from markedly improved to markedly worse, with percentages on the vertical axis.*

FDA Label Image

Donepezil Tabs 10mg 1000s

Label for Donepezil Hydrochloride Tablets USP, 10 mg strength, film-coated oral tablets by ScieGen Pharmaceuticals, Inc. The label includes dosage, storage instructions, a barcode, and the quantity of 1000 tablets. The label states that the drug is prescription only and includes pharmacist dispensing information.*

FDA Label Image

Donepezil Tabs 10mg 30s

Label for Donepezil Hydrochloride Tablets, USP 10 mg, film coated oral tablets by ScieGen Pharmaceuticals, Inc. The label indicates a package of 30 tablets, prescription only, including storage instructions and dispensing details.*

FDA Label Image

Donepezil Tabs 5mg 1000s

Donepezil Hydrochloride 5 mg film-coated tablets label for oral use. The label states each tablet contains 5 mg of donepezil hydrochloride, USP. It includes dosage and storage instructions, a quantity of 1000 tablets, and notes the product is Rx only. The label is from ScieGen Pharmaceuticals, Inc., Hauppauge, NY.*

FDA Label Image

Donepezil Tabs 5mg 30s

Donepezil Hydrochloride Tablets USP 5 mg film-coated tablets label by ScieGen Pharmaceuticals, Inc. The label states 30 tablets per container, for oral use, and prescription only. It includes dosage instructions, storage conditions, a barcode, and manufacturer details in Hauppauge, NY.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.